Cartesian Therapeutics, Inc. cotiza a 6.99 USD y tiene una capitalización bursátil de $211M. En los últimos 12 meses ha facturado $1M con un margen de flujo de caja libre del -2838.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA…
| Periodo | 2026-11 | 2026-08 | 2026-04 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.96 | $-0.95 | $-2.71 |
| Estimado | $-1.01 | $-0.65 | $-0.70 | $-0.79 |
| Sorpresa | — | -47.7% | -35.7% | -243.0% |
| Métrica | RNAC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -5127.1% | -38.6% | -5088.5% |
| Net Margin | -4658.6% | -33.6% | -4625.1% |
| FCF Margin | -2838.6% | -13.9% | -2824.7% |
| ROE | — | -40.4% | — |
| ROA | -44.0% | -32.0% | -12.0% |
| Current Ratio | 8.65 | 2.84 | +5.81 |
| Debt / Equity | — | 0.28 | — |